Vimarsana
Biggest News Aggregation in the World

Page 5 - Fire Capital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fire Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fire Capital Today - Breaking & Trending Today

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Rating of "Moderate Buy" from Analysts - Vimarsana News

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) have earned an average rating of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month […]

Larimar Therapeutics (NASDAQ:LRMR) Receives Market Outperform Rating from JMP Securities - Vimarsana News

Larimar Therapeutics (NASDAQ:LRMR) Receives Market Outperform Rating from JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Larimar Therapeutics (NASDAQ:LRMR – Free Report) in a report released on Tuesday, Benzinga reports. They currently have a $25.00 price objective on the stock. Several other brokerages also recently commented on LRMR. Citigroup increased their price objective on Larimar Therapeutics from $4.50 to $10.00 and […]

Source: wkrb13.com
TScan Therapeutics (NASDAQ:TCRX) Reaches New 1-Year High at $9.55 - Vimarsana News

TScan Therapeutics (NASDAQ:TCRX) Reaches New 1-Year High at $9.55

TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Free Report)’s share price hit a new 52-week high during trading on Tuesday . The company traded as high as $9.55 and last traded at $9.51, with a volume of 161078 shares traded. The stock had previously closed at $9.19. Wall Street Analysts Forecast Growth A number of brokerages […]

Celcuity's (CELC) "Buy" Rating Reaffirmed at HC Wainwright - Vimarsana News

Celcuity's (CELC) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Celcuity (NASDAQ:CELC – Free Report) in a report released on Thursday morning, Benzinga reports. They currently have a $27.00 price objective on the stock. HC Wainwright also issued estimates for Celcuity’s FY2028 earnings at $4.08 EPS. A number of other analysts also recently weighed in on […]

Needham & Company LLC Reaffirms Buy Rating for Cidara Therapeutics (NASDAQ:CDTX) - Vimarsana News

Needham & Company LLC Reaffirms Buy Rating for Cidara Therapeutics (NASDAQ:CDTX)

Needham & Company LLC restated their buy rating on shares of Cidara Therapeutics (NASDAQ:CDTX – Free Report) in a research report report published on Thursday, Benzinga reports. Needham & Company LLC currently has a $25.00 price target on the biotechnology company’s stock. CDTX has been the topic of several other reports. WBB Securities reaffirmed a […]